Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xvivo Perfusion AB ( (SE:XVIVO) ) has shared an announcement.
XVIVO Perfusion AB has scheduled a conference call and webcast for April 24, 2026, to discuss its interim report for the first quarter of 2026, with CEO Christoffer Rosenblad and CFO Kristoffer Nordström leading the presentation in English. The company will publish the Q1 report earlier that day and make presentation slides available on its investor website, underscoring its efforts to maintain transparency and ongoing communication with the market and stakeholders.
The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK225.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
XVIVO Perfusion AB is a Swedish medical technology company focused exclusively on extending the life of major organs to enable more successful transplants. Founded in 1998 and headquartered in Gothenburg, it develops solutions that help transplant teams and researchers push the boundaries of transplantation medicine, and its shares are listed on Nasdaq Stockholm under the ticker XVIVO.
Average Trading Volume: 154,202
Technical Sentiment Signal: Buy
Current Market Cap: SEK9.11B
Learn more about XVIVO stock on TipRanks’ Stock Analysis page.